- Home
- AVTX vs SKYE Comparison
AVTX vs SKYE Comparison
Compare AVTX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AVTX | SKYE |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 339.9M | 44.9M |
| IPO Year | 2015 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AVTX | SKYE |
|---|---|---|
| Price | $13.87 | $0.58 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | ★ $36.80 | $15.00 |
| AVG Volume (30 Days) | ★ 778.2K | 285.3K |
| Earning Date | 03-23-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 72.07 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,813,137.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2312.27 | N/A |
| 52 Week Low | $3.39 | $0.60 |
| 52 Week High | $20.72 | $5.75 |
Technical Indicators
Market Signals| Indicator | AVTX | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 38.08 | 32.30 |
| Support Level | $13.45 | N/A |
| Resistance Level | $16.40 | $0.83 |
| Average True Range (ATR) | 1.02 | 0.05 |
| MACD | -0.27 | -0.00 |
| Stochastic Oscillator | 19.18 | 1.06 |
Price Performance
Historical ComparisonAbout AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.